1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19
on Global Axial Spondyloarthritis Treatment Market
5. Voice of Customer
6. Clinical Trial
Analysis
7.
Global Axial Spondyloarthritis Treatment Market Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market Share &
Forecast
7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin
(IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
7.2.2. By Indication (Ankylosing Spondylitis v/s
Non-radiographic Axial Spondyloarthritis Treatment)
7.2.3. By End User (Hospitals & Clinics, Academic &
Research Institutions, Others)
7.2.4. By Region
7.2.5. By Company (2021)
7.3. Market Map
8.
North America Axial Spondyloarthritis Treatment Market Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share &
Forecast
8.2.1. By Therapy
8.2.2. By Indication
8.2.3. By End User
8.2.4. By Country
8.3. North America:
Country Analysis
8.3.1. United States Axial
Spondyloarthritis Treatment Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Therapy
8.3.1.2.2.
By Indication
8.3.1.2.3.
By End User
8.3.2. Canada Axial
Spondyloarthritis Treatment Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Therapy
8.3.2.2.2.
By Indication
8.3.2.2.3.
By End User
8.3.3. Mexico Axial
Spondyloarthritis Treatment Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Therapy
8.3.3.2.2.
By Indication
8.3.3.2.3.
By End User
9.
Europe Axial Spondyloarthritis Treatment Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share &
Forecast
9.2.1. By Therapy
9.2.2. By Indication
9.2.3. By End User
9.2.4. By Country
9.3. Europe: Country
Analysis
9.3.1. France Axial
Spondyloarthritis Treatment Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Therapy
9.3.1.2.2.
By Indication
9.3.1.2.3.
By End User
9.3.2. Germany Axial
Spondyloarthritis Treatment Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Therapy
9.3.2.2.2.
By Indication
9.3.2.2.3.
By End User
9.3.3. United Kingdom Axial
Spondyloarthritis Treatment Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Therapy
9.3.3.2.2.
By Indication
9.3.3.2.3.
By End User
9.3.4. Italy Axial
Spondyloarthritis Treatment Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Therapy
9.3.4.2.2.
By Indication
9.3.4.2.3.
By End User
9.3.5. Spain Axial
Spondyloarthritis Treatment Market Outlook
9.3.5.1.
Market Size & Forecast
9.3.5.1.1.
By Value
9.3.5.2.
Market Share & Forecast
9.3.5.2.1.
By Therapy
9.3.5.2.2.
By Indication
9.3.5.2.3.
By End User
10.
Asia-Pacific Axial Spondyloarthritis Treatment Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Indication
10.2.3. By End User
10.2.4. By Country
10.3.
Asia-Pacific: Country Analysis
10.3.1. China Axial
Spondyloarthritis Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Therapy
10.3.1.2.2.
By Indication
10.3.1.2.3.
By End User
10.3.2. India Axial
Spondyloarthritis Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Therapy
10.3.2.2.2.
By Indication
10.3.2.2.3.
By End User
10.3.3. Japan Axial
Spondyloarthritis Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Therapy
10.3.3.2.2.
By Indication
10.3.3.2.3.
By End User
10.3.4. South Korea Axial
Spondyloarthritis Treatment Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1.
By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1.
By Therapy
10.3.4.2.2.
By Indication
10.3.4.2.3.
By End User
10.3.5. Australia Axial
Spondyloarthritis Treatment Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1.
By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1.
By Therapy
10.3.5.2.2.
By Indication
10.3.5.2.3.
By End User
11.
South America Axial Spondyloarthritis Treatment Market Outlook
11.1.
Market Size & Forecast
11.1.1. By Value
11.2.
Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Indication
11.2.3. By End User
11.2.4. By Country
11.3.
South America: Country Analysis
11.3.1. Brazil Axial
Spondyloarthritis Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1.
By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1.
By Therapy
11.3.1.2.2.
By Indication
11.3.1.2.3.
By End User
11.3.2. Argentina Axial
Spondyloarthritis Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1.
By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1.
By Therapy
11.3.2.2.2.
By Indication
11.3.2.2.3.
By End User
11.3.3. Colombia Axial
Spondyloarthritis Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1.
By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1.
By Therapy
11.3.3.2.2.
By Indication
11.3.3.2.3.
By End User
12.
Middle East and Africa Axial Spondyloarthritis Treatment Market Outlook
12.1.
Market Size & Forecast
12.1.1. By Value
12.2.
Market Share & Forecast
12.2.1. By Therapy
12.2.2. By Indication
12.2.3. By End User
12.2.4. By Country
12.3.
MEA: Country Analysis
12.3.1. South Africa Axial
Spondyloarthritis Treatment Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1.
By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1.
By Therapy
12.3.1.2.2.
By Indication
12.3.1.2.3.
By End User
12.3.2. Saudi Arabia Axial
Spondyloarthritis Treatment Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1.
By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1.
By Therapy
12.3.2.2.2.
By Indication
12.3.2.2.3.
By End User
12.3.3. UAE Axial
Spondyloarthritis Treatment Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1.
By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1.
By Therapy
12.3.3.2.2.
By Indication
12.3.3.2.3.
By End User
13. Market Dynamics
13.1.
Drivers
13.2.
Challenges
14. Market Trends & Developments
15. Competitive
Landscape (Inclusive SWOT Analysis)
15.1.
Novartis International, AG
15.2.
Eli Lilly and Company
15.3.
Johnson & Johnson
15.4.
UCB S.A.
15.5.
Pfizer, Inc.
15.6.
Kyowa Kirin Co., Ltd.
15.7.
Merck & Co., Inc.
15.8.
AbbVie Inc
15.9.
Bristol-Myers Squibb Company
15.10.
FunPep Co., Ltd.
16. Strategic Recommendations